Prescription Quantity Changes Require Documentation
Anytime you dispense a quantity different from what was prescribed, you should note why. PAAS National®® has seen recoupments when quantities dispensed were decreased or increased from the original prescribed quantity.
Valid reasons for decreasing quantity include patient request, med sync program, “dispense in original container,” and plan limitations. In these situations, you should be documenting the reason on the prescription or within the pharmacy’s software. Many PBMs require this documentation, including OptumRx, Express Scripts, Elixir, CVS/Caremark, and MagellanRx, all of which have discrepancy codes related to “cut quantity.” The rationale behind these discrepancies is that the PBM believes the pharmacy is trying to acquire excessive dispensing fees and/or circumvent plan limitations. Having documentation stating otherwise is essential. Contractual obligations must also be taken into consideration when dispensing lesser quantities of a medication. If you are not already aware, PAAS has one of the largest troves of PBM contracts in the nation. PAAS has seen a prominent PBM recently insert language in their extended days’ supply agreements that require pharmacies to use “commercially reasonable efforts” to dispense an Extended Days’ Supply. Not only does the PBM frown upon cut quantities, but they also want pharmacies intervening to dispense more extended days’ supply prescriptions. Evidence to the contrary can result in required corrective action plans and decreased reimbursement on 30 days’ supply claims going forward (either at the point of sale, or through the reconciliation process). Indiscriminately changing patients to a 30 days’ supply resulting in increased reimbursement for the pharmacy can give the appearance of profiteering and be a slippery slope. There are also some things to consider when increasing a quantity: PAAS Tips:
- Insulin Pens: Understanding Dosing Increments and Audit Risks - October 9, 2024
- What to Do (and Not Do) When Your Days’ Supply is Rejected - October 7, 2024
- 2024 DMEPOS Series #7: Therapeutic Shoes for Diabetics - September 5, 2024